Research Paper Volume 12, Issue 14 pp 14649—14676

Identifying CpG methylation signature as a promising biomarker for recurrence and immunotherapy in non–small-cell lung carcinoma

Figure 3. (A) LASSO-Logistic and (B) Random Forest methods applied to identify recurrence associated DNAm markers in training cohort. (C) A total of 11 overlapping CpGs and 24 combined CpGs in two algorithms. (D) LASSO-Cox analysis performed to select robust relapse predictive CpGs. (E) Four final identified CpGs in the intersection of univariate Cox and LASSO-Cox results. (F) The RFS curve (left) and overall survival curve (right) of training cohort based on 4-DNAm-maker panel.